argenx planning Phase III for thrombocytopenia therapy

argenx S.E. (Euronext:ARGX; NASDAQ:ARGX) said it plans to start Phase III testing of IV efgartigimod (ARGX-113) to treat primary immune thrombocytopenia (ITP) after reporting that the compound led to clinically meaningful platelet count improvements in a Phase II trial in the indication. Efgartigimod is a human antibody Fc fragment that targets neonatal Fc receptor (FCRN; FCGRT).

The company followed the data announcement with another after market close on Monday in which it proposed to raise $300 million in a follow-on underwritten by Morgan Stanley, Cowen, Evercore ISI, Kempen and Nomura...